ReviewClinical & developmental immunology2010
Repertoire development and the control of cytotoxic/effector function in human gammadelta T cells.
Review in Clinical & developmental immunology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 34 citations in OpenAlex.
- Pan-cancer γδ TCR analysis uncovers clonotype diversity and prognostic potential.Cell reports. Medicine · 2024Article
- A pan-cancer gamma delta T cell repertoire.bioRxiv : the preprint server for biology · 2024Article
- Non-signaling Chimeric Antigen Receptors Enhance Antigen-Directed Killing by γδ T Cells in Contrast to αβ T Cells.Molecular therapy oncolytics · 2020Article
- CD137 costimulation enhances the antiviral activity of Vγ9Vδ2-T cells against influenza virus.Signal transduction and targeted therapy · 2020Article
- Review
- High-dose post-transplant cyclophosphamide impairs γδ T-cell reconstitution after haploidentical haematopoietic stem cell transplantation using low-dose antithymocyte globulin and peripheral blood stem cell graft.Clinical & translational immunology · 2020Article
- Targeting T cell malignancies using CAR-based immunotherapy: challenges and potential solutions.Journal of hematology & oncology · 2019Review
- Characterization of human infiltrating and circulating gamma-delta T cells in prostate cancer.Investigative and clinical urology · 2019Article
- Elevated CD3PeerJ · 2018Article
- Whole transcriptome profiling reveals major cell types in the cellular immune response against acute and chronic active Epstein-Barr virus infection.Scientific reports · 2017Article
- Characterization of γδ T cells in patients with non-small cell lung cancer.Oncology letters · 2017Article
- Comparative Analysis of Human Epidermal and Peripheral Blood γδ T Cell Cytokine Profiles.Annals of dermatology · 2014Article
- Clinical evidence implicating gamma-delta T cells in EBV control following cord blood transplantation.Bone marrow transplantation · 2013Article
- Targeting gamma delta T cells for cancer immunotherapy: bench to bedside.The Indian journal of medical research · 2013Review
- Fc receptor-mediated immune responses: new tools but increased complexity in HIV prevention.Current HIV research · 2013Article
- Lyme disease: aetiopathogenesis, factors for disease development and control.Inflammopharmacology · 2013Review
- Ex vivo restimulation of human PBMC expands a CD3+CD4-CD8- γδ+ T cell population that can confound the evaluation of CD4 and CD8 T cell responses to vaccination.Clinical & developmental immunology · 2013Article
- Targeting EpCAM (CD326) for immunotherapy in hepatoblastoma.Oncoimmunology · 2013Article
- Impact of persistent HIV replication on CD4 negative Vγ2Vδ2 T cells.The Journal of infectious diseases · 2012Article
- Flanking V and J sequences of complementary determining region 3 of T cell receptor (TCR) δ1 (CDR3δ1) determine the structure and function of TCRγ4δ1.The Journal of biological chemistry · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
T cells develop into two major populations distinguished by their T cell receptor (TCR) chains. Cells with the alphabeta TCR generally express CD4 or CD8 lineage markers and mostly fall into helper or cytotoxic/effector subsets. Cells expressing the alternate gammadelta TCR in humans generally do not express lineage markers, do not require MHC for antigen presentation, and recognize nonpeptidic antigens. We are interested in the dominant Vgamma2Vdelta2+ T cell subset in human peripheral blood and the control of effector function in this population. We review the literature on gammadelta T cell generation and repertoire selection, along with recent work on CD56 expression and defining a cytotoxic/effector lineage within the phosphoantigen-reactive Vgamma2Vdelta2 cells. A unique mechanism for MHC-independent repertoire selection is linked to the control of effector function that is vital to the role for gammadelta T cells in tumor surveillance. Better understanding of these mechanisms will improve our ability to exploit this population for tumor immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.